Defective lysosomal arginine transport in juvenile Batten disease

Human Molecular Genetics

Volumn 14, Issue 23, 2005, Pages 3759-3773

  Ramirez Montealegre, Denia ^a   Pearce, David A ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ARGININE; CATION; LENTIVIRUS VECTOR; LYSINE; MEMBRANE PROTEIN; PROTEIN ANTIBODY;

AMINO ACID TRANSPORT; ARTICLE; BTN1P GENE; CLN3 GENE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LYMPHOBLAST; LYSOSOME MEMBRANE; MALE; NEURONAL CEROID LIPOFUSCINOSIS; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; ANTIBODIES, BLOCKING; ARGININE; BIOLOGICAL TRANSPORT; CATIONS; CHILD; FEMALE; HUMANS; LYMPHOCYTES; LYSOSOMES; MALE; MEMBRANE GLYCOPROTEINS; MOLECULAR CHAPERONES; MUTATION; NEURONAL CEROID-LIPOFUSCINOSES; VACUOLAR PROTON-TRANSLOCATING ATPASES;

LENTIVIRUS; MAMMALIA;

EID: 28744438595     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddi406     Document Type: Article

References (76)

1. Goebel, H.H. (1995) The neuronal ceroid lipofuscinoses. J. Chil. Neurol., 10, 424-437.
2. International Batten Disease Consortium (1995) Isolation of a novel gene underlying Batten disease. Cell, 82, 949-957.
3. Mole, S.E. (2004) The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol.,14, 70-76.
4. Munroe, P.B., Mitchison, H.M., O'Rawe, A.M., Anderson, J.W., Boustany, R.M., Lerner, T.J., Taschner, P.E., de Vos, N., Breuning, M.H., Gardiner, R.M. and Mole, S.E. (1997) Spectrum of mutations in the Batten disease gene, CLN3. Am. J. Hum. Gen., 61, 310-316.
5. Phillips, S.N., Benedict, J.W., Wiemer, J.M. and Pearce, D.A. (2005) CLN3, the protein associated with Batten disease: Structure, function and localization. J. Neurosci. Res., 79, 573-583.
6. Taschner, P.E., de Vos, N. and Breuning, M.H. (1997) Cross-species homology of the CLN3 gene. Neuropediatrics, 28, 18-20.
7. Pearce, D.A. and Sherman, F. (1997) BTN1, a yeast gene corresponding to the human gene responsible for Batten's disease, is not essential for viability, mitochondrial function, or degradation of mitochondrial ATP synthase. Yeast, 13, 691-697.
8. Croopnick, J.B., Choi, H.C. and Mueller, D.M. (1998) The subcellular location of the yeast Saccharomyces cerevisiae homologue of the protein defective in the juvenile form of Batten disease. Biochem. Biophys. Res. Commun., 250, 335-341.
9. Pearce, D.A., Ferea, T., Nosel, S.A., Das, B. and Sherman, F. (1999) Action of Btn1p, the yeast orthologue of the gene mutated in Batten disease. Nat. Genet., 22, 55-58.
10. Golabek, A.A., Kida, E., Walus, M., Kaczmarski, W., Michalewski, M. and Wisniewski, K.E. (2000) CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol. Gen. Metab., 70, 203-213.
11. Holopainen, J.M., Saarikoski, J., Kinnunen, P.K. and Jarvela, I. (2001) Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur. J. Biochem., 268, 5851-5856.
12. Kim, Y.K., Ramirez-Montealegre, D. and Pearce, D.A. (2003) A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc. Natl Acad. Sci., 100, 15458-15462.
13. Pisoni, R.L., Thoene, J.G. and Christensen H.N. (1985) Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. J. Biol. Chem., 260, 4791-4798.
14. Pisoni, R.L., Thoene, J.G., Lemmons, R.M. and Christensen, H.N. (1987) Important differences in cationic amino acid transport by lysosomal system c and system y+ of the human fibroblast. J. Biol. Chem., 262, 15011-15018.
15. White, M.F. (1985) The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim. Biophys. Acta, 822, 355-374.
16. Harms, E., Kartenbeck, J., Darai, G. and Schneider, J. (1981) Purification and characterization of human lysosomes from EB-virus transformed lymphoblasts. Exp. Cell Res., 131, 251-266.
17. Steinherz, R., Tietze, F., Raiford, D., Gahl, W.A. and Schulman, J.D. (1982) Patterns of amino acid efflux from isolated normal and cystinotic human leucocyte lysosomes. J. Biol. Chem., 257, 6041-6049.
18. Bernar, J., Tietze, F., Kohn, L.D., Bernardini, I., Harper, G.S. and Gahl, W.A. (1986) Characteristics of a lysosomal membrane transport system for tyrosine and other neutral amino acids in rat thyroid cells. J. Biol. Chem., 261, 17107-17112.
19. Gahl, W.A., Tietze, F., Bashan, N., Steinherz, R. and Schulman, J.D. (1982) Defective cystine exodus from isolated lysosome-rich fractions of cystinotic leucocytes. J. Biol. Chem., 257, 9570-9575.
20. Jonas, A., Smith, M.L., Allison, W.S., Laikind, P.K., Greene, A.A. and Schneider, JA. (1983) Proton-translocating ATPase and lysosomal cystine transport. J. Biol. Chem., 258, 11727-11730.
21. Tietze, F., Seppala, R., Renlund, M., Hopwood, J.J., Harper, G.S., Thomas, G.H. and Gahl, W.A. (1989) Defective lysosomal egress of free sialic acid (N-acetylneuraminic acid) in fibroblasts of patients with infantile free sialic acid storage disease. J. Biol. Chem., 264, 15316-15322.
22. Smith, M.L., Greene, A.A., Potashnik, R., Mendoza, S.A. and Schneider J.A. (1987) Lysosomal cystine transport: Effect of intralysosomal pH and membrane potential. J. Biol. Chem., 262, 1244-1253.
23. Pisoni, R.L., Flickinger, K.S., Thoene, J.G. and Chistensen, H.N. (1987) Characterization of carrier-mediated transport systems for small neutral amino acids in human fibroblast lysosomes. J. Biol. Chem., 262, 6010-6017.
24. Prasad, V.V. and Pullarkat, R.K. (1996) Brain lysosomal hydrolases in neuronal ceroid lipofuscinosis. Mol. Chem. Neuropathol., 29, 169-179.
25. Thoene, J.G. (1992) Pathophysiology of lysosomal transport. CRC Press, Boca Raton, FL.
26. Collarini, E.J., Pisoni, R.L. and Chistensen, H.N. (1989) Characterization of a transport system for anionic amino acids in human fibroblast lysosomes. Biochim. Biophys. Acta, 987, 136-144.
27. Rome, L.H., Gavin, A.J., Allietta, M.M. and Neufeld, E.F. (1979) Two species of lysosomal organelles in cultured human fibroblasts. Cell, 17, 143-153.
28. Stewart, B.H., Collarini, E.J., Pisoni, R.L. and Christensen, H.N. (1989) Separate and shared lysosomal transport of branched and aromatic dipolar amino acids. Biochim. Biophys. Acta, 987, 145-153.
29. Gahl, W.A., Tietze, F., Bashan, N., Bernardini, I., Raiford, D. and Schulman, J.D. (1983) Characteristics of cystine countertransport in normal and cystinotic lysosome-rich leucocyte granular fractions. Biochem. J., 216, 393-400.
30. Gahl, W.A. and Tietze, F. (1985) pH effects on cystine transport in lysosome-rich leukocyte granular fractions. Biochem. J., 228, 263-267.
31. Jonas, A.J. (1986) Cystine transport in purified rat liver lysosomes. Biochem. J., 236, 671-677.
32. Jarvela, I., Sainiom, M., Rantamaki, T., Olkkonen, V.M., Carpen, 0., Peltronen, L. and Jalanko, A. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum. Mol. Genet., 7, 85-90.
33. Ezaki, J., Takeda-Ezaki, M., Koike, M., Ohsawa, Y., Taka, H., Mineki, R., Murayama, K., Uchiyama, Y., Ueno, T. and Kominami, E. (2003) Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinoses, as a lysosomal integral membrane glycoprotein. J. Neurochem., 87, 1296-1308.
34. Margraf, L.R., Boriack, R.L., Routheut, A.A., Cuppen, I., Alhilali, L., Bennett, C.J. and Bennett, M.J. (1999) Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol. Genet. Metab., 66, 283-289.
35. Haskell, R.E., Carr, C.J., Pearce, D.A., Bennett, M.J. and Davidson, B.L. (2000) Batten disease: Evaluation of CLN3 mutations on protein localization and function. Hum. Mol. Genet., 9, 735-744.
36. Mao, Q., Foster, B.J., Xia, H. and Davidson, B.L. (2003) Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett., 541, 40-46.
37. Haltia, M., Rapola, J. and Santavuori, P. (1973) Infantile type of so-called neuronal ceroid-lipofuscinosis: Histological and electron microscopic studies. Acta Neuropathol., 26, 157-170.
38. Koenig, H. (1964) Neuronal lipofuscin in disease: Its relation to lysosomes. Trans. Am. Neur. Assoc., 89, 212-213.
39. Zeman, W. (1976) The neuronal ceroid lipofuscinosis. Prog. Neuropathol., 3, 203-223.
40. Hall, N.A., Lake, B.D., Dewji, N.N. and Patrick, A.D. (1991) Lysosomal storage of subunit c of mitochondrial ATP synthase in Batten's disease (ceroid-lipofuscinosis). Biochem. J., 275, 269-272.
41. Palmer, D.N., Fearnley, I.M., Walker, J.E., Hall, N.A., Lake, B.D., Wolfe, L.S., Haltia, M., Martinur, R.D. and Jolly, R.D. (1992) Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am. J. Med. Genet., 42, 561-567.
42. Ezaki, J., Wolfe, L.S., Higuiti, T., Ishidoh, K. and Kominami, E. (1995). Specific delay of degradation of mitochondrial ATP synthase subunit c in late infantile neuronal ceroid lipofuscinosis (Batten disease). J. Neurochem., 64, 733-741.
43. Palmer, D.N., Bayliss, S.L. and Westlake, V.J. (1995) Batten disease and the ATP synthase subunit c turnover pathway: Raising antibodies to subunit c. Am. J. Med. Genet., 57, 260-265.
44. Ezaki, J., Wolfe, L.S., Ishidoh, K. and Kominami, E. (1995). Abnormal degradative pathway of mitochondrial ATP synthase subunit c in late infantile neuronal ceroid-lipofuscinosis (Batten disease). Am. J. Med. Genet., 7, 254-259.
45. Kominami, E., Ezaki, J., Muno, D., Ishido, K., Ueno, T. and Wolfe, L.S. (1992) Specific storage of subunit c of mitochondrial ATP synthase in lysosomes of neuronal ceroid lipofuscinosis (Batten's disease). J. Biochem., 111, 278-282.
46. Tapiero, H., Mathé, G., Couvreur, P. and Tew, K.D. (2002) Arginine. Biomed. Pharmacother., 56, 439-445.
47. Czapiga, M. and Colton, C.A. (2002) Microglial function in human APOE3 and APOE4 transgenic mice: Altered arginine transport. J. Neuroimmunol., 134, 44-51.
48. de Jonge, W.J., Kwikkers, K.L., de Velde, A.A., van Deventer, S.J.H., Nolte, M.A., Mebius, R.E., Ruijter, J.M., Lamers, M.C. and Lamers W.H. (2002) Arginine deficiency affects early B cell maturation and lymphoid organ development in transgenic mice. J. Clin. Invest., 110, 1539-1548.
49. Blaise, G.A., Gauvin, D., Gangal, M. and Authier, S. (2005) Nitric oxide, cell signaling and cell death. Toxicology, 208, 177-192.
50. Wu, G. and Morris, S.M. (1998) Arginine metabolism: Nitric oxide and beyond. Biochem. J., 336, 1-17.
51. Wiesinger, H. (1999) Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol., 64, 365-391.
52. Grima, G., Cuénod, M., Pfeiffer, S., Mayer, B. and Do, K.Q. (1998) Arginine availability controls the N-methyl-D-aspartate-induced nitric oxide synthesis: Involvement of a glial-neuronal arginine transfer. J. Neurochem., 71, 2139-2144.
53. Wojtal, K., Gniatkowska-Nowalkowska, A. and Czuczwar, S.J. (2003) Is nitric oxide involved in the anticonvulsant action of drugs? Pol. J. Pharm., 55, 532-542.
54. Manner, C.K., Nicholson, B. and MacLeod, C.L. (2003) CAT2 arginine transporter deficiency significantly reduces iNOS-mediated NO production in astrocytes. J. Neurochem., 85, 476-482.
55. Theard, M.A., Baugman. V.L., Wang, Q., Pelligrino, D.A. and Albrecht, R.F. (1995) The role of nitric oxide in modulating brain activity and blood flow during seizure. Neuroreport, 6, 921-924.
56. Lallement, G., Shih, T.M., Pernot-Marino, I., Baubichon, D., Foquin, A. and McDonnough, J.H. (1996) The role of nitric oxide in soma induced seizures, neuropathology and lethality. Parmacol. Biochem. Behav., 54, 731-737.
57. Gardiner, K.A., Laming, P.R. and Blumnson, N.L. (1993) Brain amino acid levels are related to seizure propensity in the gerbil (Meriones unguculatus). Comp. Biochem. Physiol. B, 106, 799-804.
58. Honar, H., Riazi, K., Homayoun, H., Demehri, S., Dehgani, M., Vafaie, K., Ebrahimkhani, M.R., Rashidi, N., Gaskari, S.A. and Dehpour, A.H. (2004) Lithium inhibits the modulatory effect of morphine on susceptibility to pentylenetetrazole-induced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res., 1029, 48-55.
59. Jelenkovic, A., Jovanovic, M., Ninkovic, M., Maksimovic, M., Bokonjic, D. and Boskovic, B. (2002) Nitric oxide (NO) and convulsions induced by pentylenetetrazol. Ann. NY Acad. Sci., 962, 296-305.
60. Penix, L.P., Davis, W. and Subramanian, S. (1994) Inhibition of NO synthase increases the severity of kainic acid-induced seizures in rodents. Epilepsy Res., 18, 177-184.
61. Urbanska, J.M., Drelewska, E., Borowicz, K.K., Blaszczak, P., Kleinrod, Z. and Czuczwar, S.J. (1996) NG-Nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. J. Neural Transm., 103, 1145-1152.
62. Demehri, S., Homayoun, H., Honar, H., Riazi, K., Vafaie, K., Roushanzamir, F. and Dehpour, A.R. (2003) Agmatine exerts anticonvulsant effect in mice: Modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmocology, 45, 534-542.
63. Pearce, D.A. (2003) Altered amino acid levels in sera of a mouse model of juvenile neuronal ceroid lipofuscinoses. Clin. Chim. Acta, 332, 145-148.
64. Helip-Wooley, A. and Thoene, J.G. (2004) Sucrose-induced vacuolation results in increased expression of cholesterol biosynthesis and lysosomal genes. Exp. Cell Res., 292, 89-100.
65. Kim, Y.K., Chattopadhyay, S., Locke, S. and Pearce, D.A. (2005) Interaction among Btn1p, Btn2p, and Ist2p reveals potential interplay among the vacuole, amino acid levels, and ion homeostasis in the yeast Saccharomyces cerevisiae. Eukaryot. Cell, 4, 281-288.
66. Sun-Wada, G.H., Wada, Y. and Futai, M. (2004) Diverse and essential roles of mammalian vacuolar-type proton pump ATPase: Toward the physiological understanding of inside acidic compartments. Biochim. Biophys. Acta, 1658, 106-114.
67. Sun-Wada, G.H., Wada, Y. and Futai, M. (2003) Lysosome and lysosome- related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. Cell. Struct. Funct., 28, 455-463.
68. +) -ATPases-nature's most versatile proton pumps. Nat. Rev. Mol. Cell. Biol., 3, 94-103.
69. Morel, N., Dedieu, J.C. and Philippe, J.M. (2003) Specific sorting of the a1 isoform of the V-H + ATPase a subunit to nerve terminals where it associates with both synaptic vesicles and the presynaptic plasma membrane. J. Cell Sci., 116, 4751-4762.
70. +-ATPase in catecholamine storage vesicles. Neuropharmacology, 38, 879-882.
71. Aberg, L., Liewendahl, K., Nikkinen, P., Autti, T., Rinne, J.O. and Santavuori, P. (2000) Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology, 54, 1069-1074.
72. Wall, F.E., Henkel, R.D., Stern, M.P., Jenson, H.B. and Moyer, M.P. (1995) An efficient method for routine Epstein-Barr virus immortalization of human B lymphocytes. In Vitro Cell. Dev. Biol. Anim., 31, 156-159.
73. Lizeé, G., Gonzales, M.I. and Topalian, S.L. (2004) Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gen. Ther., 15, 393-404.
74. + antiport activity in human hypertension. J. Hypertens., 7, 471-475.
75. + exchanger isoform-1 activity in postpartum women with pre-eclampsia. Br. J. Obst. Gyn., 108, 615-622.
76. + antiport activity of human neutrophils. Am. J. Physiol., 250, 283-291.